The incretin hormones GIP and GLP-1 in diabetic rats: Effects on insulin secretion and small bowel motility

Neurogastroenterology and Motility

Volumn 21, Issue 3, 2009, Pages 313-321

  Edholm, T ^a   Cejvan, K ^a   Abdel Halim, S M ^a   Efendic, S ^a   Schmidt, P T ^a   Hellstrom P M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diabetes; Gastric inhibitory peptide; Gastrointestinal peptide hormones; Glucagon like peptide 1; Glucose dependent insulinotropic peptide; Migrating myoelectric complex

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GENE EXPRESSION; GOTO KAKIZAKI RAT; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESPONSE; INTESTINE MOTILITY; MALE; NONHUMAN; PANCREAS ISLET; PANCREAS PERFUSION; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; RNA EXTRACTION; SMALL INTESTINE; WISTAR RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; GASTROINTESTINAL MOTILITY; GLUCAGON-LIKE PEPTIDE 1; INSULIN; INTESTINE, SMALL; MALE; MYOELECTRIC COMPLEX, MIGRATING; PANCREAS; RATS; RATS, INBRED STRAINS;

EID: 60649090678     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2008.01229.x     Document Type: Article

References (53)

1. Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973 37 : 826 8.
2. Nauck MA, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986 29 : 46 54.
3. Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964 24 : 1076 82.
4. McIntryre N, Holdsworth CD, Turner DA. New interpretation of oral glucose tolerance. Lancet 1964 2 : 20 1.
5. La Barre J. Sur les possibilites d'un traitment du diabetes par l'incretin. Bull Acad R Med Belg 1932 12 : 620 34.
6. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R. Incretin effects of increasing glucose loads in man calculated from venous insulin and c-peptide responses. J Clin Endocrinol Metab 1986 63 : 492 8.
7. Andersen DK, Elahi D, Brown JC, Tobin JD, Andres R. Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest 1978 62 : 152 61.
8. Elahi D, Andersen DK, Brown JC et al. Pancreatic alpha-cell and beta-cell responses to gip infusion in normal man. Am J Physiol 1979 237 : E185 91.
9. Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia 1985 28 : 565 73.
10. Creutzfeldt W, Nauck M. Gut hormones and diabetes mellitus. Diabetes Metab Rev 1992 8 : 149 77.
11. Yip R, Wolfe M. GIP biology and fat metabolism. Life Sci 2000 66 : 91 103.
12. Brown JC, Mutt V, Pederson RA. Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol 1970 209 : 57 64.
13. Pederson RA, Schubert HE, Brown JC. Gastric inhibitory polypeptide: its physiologic release and insulinotropic action in the dog. Diabetes 1975 24 : 1050 6.
14. Cataland S, Crockett SE, Brown JC, Mazzaferri EL. Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. J Clin Endocrinol Metab 1974 39 : 223 8.
15. Miki T, Minami K, Shinozaki H et al. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes 2005 54 : 1056 63.
16. Vella A, Rizza R. Extrapancreatic effects of GIP and GLP-1. Horm Metab Res 2004 36 : 830 6.
17. Meier JJ, Nauck MA. GIP as a potential therapeutic agent? Horm Metab Res 2004 36 : 859 66.
18. Nauck MA, Heimesaat MM, Behle K. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002 87 : 1239 46.
19. Burcelin R, Da Costa A, Drucker D, Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001 50 : 1720 8.
20. Nauck MA, Holst JJ, Willms B, Schmiegel W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2 diabetes. Exp Clin Endocrinol Diabetes 1997 105 : 187 95.
21. Perfetti R, Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic. ß cell function. Eur J Endocrinol 2000 43 : 717 25.
22. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993 38 : 665 73.
23. Schirra J, Katschinski M, Weidmann C et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996 97 : 92 103.
24. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellström PM. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998 43 : 2284 90.
25. Holz G. A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 2004 53 : 5 13.
26. Drucker D. The biology of incretin hormones. Cell Metab 2006 3 : 153 65.
27. Zander M, Madsbad S, Madsen J, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002 359 : 824 30.
28. Nauck MA, Schmidt WE, Ebert R et al. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: Interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab 1989 69 : 654 62.
29. Theodorakis M, Carlson O, Michopoulos S et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol 2006 290 : E550 9.
30. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995 30 : 892 6.
31. Vilsbøll T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of type 2 diabetes mellitus. Dan Med Bull 2004 51 : 364 70.
32. Kruger D, Gatcombe P, Owen S. Clinical implications of amylin and amylin deficiency. Diabetes Educ 1999 25 : 389 97.
33. Horowitz M, Edelbroek M, Wishart J, Straathof J. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993 36 : 857 62.
34. Toft-Nielsen M, Damholt M, Madsbad S. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001 86 : 3717 23.
35. Kruger D, Martin C, Sadler C. New insights into glucose regulation. Diabetes Educ 2006 32 : 221 8.
36. Abdel-Halim S, Guenifi A, Khan A et al. Impaired coupling of glucose signal to the exocytotic machinery in diabetic GK rats: a defect ameliorated by cAMP. Diabetes 1996 45 : 934 40.
37. Loubatieres AL, Mariani MM, Ribes G, De Malbosc H, Chapal J. Etude experimentale d'un nouveau sulfamide hypoglicemiant particulierement actif, le HB419 ou glibenclamide. Diabetologia 1969 5 : 1 10.
38. Szecówka J, Grill V, Sandberg E, Efendić S. Effect of GIP on the secretion of insulin and somatostatin and the accumulation of cyclic AMP in vitro in the rat. Acta Endocrinol 1982 99 : 416 21.
39. Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 1996 19 : 857 63.
40. Nakazaki M, Crane A, Hu M et al. cAMP-activated protein kinase-independent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets. Diabetes 2002 51 : 3440 9.
41. Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH, Rorsman P. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 1998 47 : 57 65.
42. Yedovitzky M, Mochly-Rosen D, Johnson JA et al. Translocation inhibitors define specificity of protein kinase c isoenzymes in pancreatic beta-cells. J Biol Chem 1997 272 : 1417 20.
43. Warwar N, Efendic S, Östenson C-G, Haber EP, Cerasi E, Nesher R. Dynamics of glucose-induced localization of pkc isoenzymes in pancreatic beta-cells: diabetes-related changes in the GK rat. Diabetes 2006 55 : 590 9.
44. Lynn F, Pamir N, Ng E, McIntosh C, Kieffer T, Pederson R. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001 50 : 1004 11.
45. Deacon C, Plamboeck A, Rosenkilde M, De Heer J, Holst JJ. GIP-3-42 does not antagonize the insulinotropic effects of GIP at physiological concentrations. Am J Physiol 2006 291 : E468 75.
46. Flint A, Raben A, Ersboll A, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001 25 : 781 92.
47. Schjoldager BT, Mortensen PE, Christiansen J, Ørskov C, Holst JJ. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in man. Dig Dis Sci 1989 35 : 703 8.
48. 2: a physiological inhibitor of gastric acid secretion in man. J Endocrinol 1990 126 : 169 73.
49. Wettergren A, Petersen H, Ørskov C, Christiansen J, Sheikh SP, Holst JJ. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 1994 29 : 501 5.
50. Nauck MA, Niedereichholz U, Ettler R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997 273 : 981 8.
51. Little TJ, Pilichiewicz AN, Russo A et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006 91 : 1916 23.
52. Meier JJ, Goetze O, Anstipp J et al. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol 2004 286 : E621 5.
53. Houghton LA, Read NW, Heddle R et al. Motor activity of the gastric antrum, pylorus and duodenum in response to a liquid meal. Gastroenterology 1988 94 : 1276 84.